(COVID-19) Longitudinal Neutralizing Antibody Titers in Cancer Patients Receiving Different Anti-caner Therapies
Launched by CHANG GUNG MEMORIAL HOSPITAL · May 18, 2022
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how cancer patients respond to COVID-19 vaccination, specifically looking at the levels of antibodies produced after receiving the vaccine. Since patients with cancer are at higher risk for serious illness from COVID-19, understanding how well the vaccine works for them is very important. The study includes patients with various types of cancer who are receiving different treatments, such as chemotherapy, immunotherapy, or targeted therapy, as well as healthy volunteers.
To be eligible for this trial, participants must be over 20 years old and either currently undergoing cancer treatment or have been cancer-free for at least six months. They should also have been fully vaccinated against COVID-19 or be willing to get vaccinated during the study. Participants will provide blood samples to check their antibody levels and will have regular follow-ups to monitor their health. It's important for potential participants to know that they can withdraw from the study at any time if they choose to do so.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. adults \>20 years old;
- • 2. cancer patients under active anti-cancer therapy, including chemotherapy (n=80), targeted therapy (n=80) and immunotherapy (n=80); and cancer patients have been disease-free for ≥ 6 months (n=80)
- • 3. cancer patients who were full vaccinated with any brand of vaccines or cancer patients who were unvaccinated agree to complete full vaccination later.
- • 4. patients who agreed with the content of informed consent of the study protocol.
- Exclusion Criteria:
- • 1. Patients who refused the protocol of N-antibody test and Out-Patient Departments follow-up.
- • 2. The investigators suggest to withdraw.
- • 3. Patient asked to withdraw from the trial at any timepoints.
About Chang Gung Memorial Hospital
Chang Gung Memorial Hospital, one of the largest healthcare organizations in Taiwan, is renowned for its commitment to advancing medical research and improving patient care. As a clinical trial sponsor, the hospital leverages its extensive clinical expertise and state-of-the-art facilities to conduct innovative research across various medical disciplines. With a focus on collaboration and ethical practices, Chang Gung Memorial Hospital aims to contribute to the global body of medical knowledge through rigorous clinical trials that enhance treatment options and improve health outcomes for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New Taipei City, , Taiwan
Patients applied
Trial Officials
Chia-Hsun Hsieh, PhD
Study Director
Professor Attending Physicians
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials